More options for people with Fabry disease in Europe

9 May 2023
2019_vial_production_biotech_manufacturing_big

A new Fabry disease therapy, PRX-102 (pegunigalsidase alfa), has been given marketing authorization by the European Medicines Agency.

Developed by Israel’s Protalix BioTherapeutics (TASE: PLX) and Italian partner Chiesi Farmaceutici, approval for the enzyme replacement therapy was expected after the EMA’s scientific advisors issued a positive decision earlier in the year.

The product will vie with two other therapies in this class which are already available in Europe -  Sanofi’s (Euronext: SAN) Fabrazyme (agalsidase beta) and Takeda’s (TYO: 4502) Replagal (agalsidase alfa).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology